1/61
Comprehensive vocabulary flashcards covering psychotropic renal dosing rules, class-specific adverse drug reactions, boxed warnings, and emergency neuropsychiatric syndromes verified against FDA labeling.
Cockcroft-Gault formula
The standard mathematical formula used to estimate creatinine clearance: CrCl (mL/min)=72×serum creatinine in mg/dL[(140−age in years)×weight in kg], multiplied by 0.85 for women, using actual or adjusted body weight when BMI deviates significantly from normal.
Creatinine clearance bands
Renal staging categories for medication dosing: ≥90mL/min indicates normal clearance (standard dosing); 60–89mL/min indicates mild impairment (most drugs unchanged); 30–59mL/min indicates moderate impairment (adjustments begin for many drugs); and <30mL/min indicates severe impairment (adjust or avoid several agents).
Renally cleared psychotropics
Psychotropic medications that depend on kidney excretion and require dosing modifications or vigilance in renal impairment, including lithium, gabapentin, pregabalin, memantine, galantamine, paliperidone, duloxetine, venlafaxine, desvenlafaxine, brexpiprazole, risperidone, buspirone, mirtazapine, and bupropion.
Non-renally adjusted psychotropics
Common psychotropic agents requiring no standard renal dose adjustments: sertraline, escitalopram, citalopram, fluoxetine, vortioxetine, donepezil, rivastigmine, aripiprazole, olanzapine, quetiapine, and haloperidol (vigilance still required in frail older adults).
Lithium renal management rule
A narrow therapeutic index mood stabilizer that is entirely renally cleared; any change in renal function, dehydration, NSAIDs, ACE inhibitors/ARBs, or thiazides alters blood levels, requiring levels to be checked 5–7 days after dosage changes and immediate holding during acute kidney injury or dehydrating illness.
Duloxetine renal threshold
An SNRI prescribing rule mandating avoidance if GFR is <30mL/min.
Venlafaxine renal adjustment
Extended-release SNRI dosing recommendation capping the dose at a maximum of 112.5mg once daily in the presence of renal impairment.
Desvenlafaxine renal dosing
An SNRI dosing protocol requiring a maximum of 50mg/day for CrCl 30–89mL/min, and 50mg every other day in severe renal impairment or end-stage renal disease (ESRD).
Mirtazapine renal rule
A tetracyclic antidepressant whose clearance decreases in renal impairment, requiring cautious administration and slower titration.
Bupropion renal adjustment
An antidepressant guideline recommending a reduction in dose, frequency of dosing, or both in the presence of renal impairment.
Paroxetine renal adjustment
An SSRI dosing directive to restrict therapy to the lower end of the dosing range in cases of severe renal impairment.
Buspirone renal rule
An anxiolytic guideline directing dose reduction and cautious use due to an approximate 4-fold increase in drug area under the curve (AUC) during renal impairment.
Gabapentin renal dosing
A completely renally cleared anticonvulsant and analgesic requiring dosing via CrCl-based protocols (e.g., 300–600mg three times daily for CrCl≥60mL/min; halving the daily dose and extending the dosing interval for CrCl<30mL/min).
Paliperidone renal thresholds
An SGA renal guideline establishing an initial dose of 3mg daily for CrCl 50–79mL/min, 1.5mg daily for CrCl 10–49mL/min, and non-recommendation below CrCl 10mL/min.
Risperidone renal adjustment
An antipsychotic regimen for severe renal impairment initiating at 0.5mg twice daily, allowing titration above 1.5mg twice daily only at intervals of at least one week.
Brexpiprazole renal limit
An SGA dosing cap specifying a maximum dose of 2mg/day in moderate-to-severe renal or hepatic impairment.
Memantine renal dosing
An NMDA receptor antagonist protocol for severe renal impairment establishing a target dose of 5mg twice daily for the immediate-release formulation or 14mg once daily for the extended-release formulation.
Galantamine renal thresholds
A cholinesterase inhibitor threshold limiting dosage to a maximum of 16mg/day for CrCl 9–59mL/min, with an absolute contraindication to use if CrCl<9mL/min.
Glucuronidated Benzodiazepines (LOT)
Lorazepam, oxazepam, and temazepam; the safest benzodiazepines in renal disease because they are metabolized via glucuronidation into inactive metabolites and do not require renal dose adjustments.
Antidepressant Boxed Warning
An FDA boxed warning mandated on all antidepressant medications regarding increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under age 25.
Shared SSRI Complications
Four adverse effects common across the SSRI class: hyponatremia/SIADH (most commonly emerging in the first 2–4 weeks), increased bleeding risk with NSAIDs and anticoagulants, sexual dysfunction, and discontinuation syndrome.
Citalopram QT prolongation
A dose-dependent cardiac conduction abnormality caused by citalopram, prompting a maximum dosing limit of 20mg/day in individuals over age 60.
Paroxetine signature adverse profile
A distinctive side-effect spectrum comprising potent anticholinergic activity, weight gain, strong CYP2D6 enzyme inhibition, cardiac concerns in pregnancy, and the most severe discontinuation syndrome among SSRIs.
Bupropion seizure risk
A dose-dependent proconvulsant effect that makes bupropion strictly contraindicated in patients with active or historical seizure disorders and eating disorders.
Mirtazapine signature profile
Prominent sedation and weight gain caused by mirtazapine, which can be therapeutically beneficial when depression presents with concurrent insomnia and anorexia.
SNRI blood pressure elevation
A dose-dependent hypertensive complication characteristic of the SNRI class, requiring regular blood pressure monitoring during dose titration.
MAOI lethal complications
Severe reactions associated with monoamine oxidase inhibitors: hypertensive crisis triggered by tyramine-containing foods ('cheese reaction') and serotonin syndrome when co-administered with serotonergic agents.
MAOI washout periods
Mandatory drug clearance intervals before initiating an MAOI: wait 14 days after stopping most antidepressants, and wait 5 weeks after stopping fluoxetine due to its long half-life.
Trazodone-induced priapism
A rare urologic emergency presenting as prolonged, painful penile erection that mandates immediate discontinuation of trazodone and emergent medical intervention.
Esketamine (Spravato) REMS
A specialized monitoring protocol requiring a 2-hour post-dose observation period for sedation and dissociation under a REMS program, accompanied by boxed warnings for sedation, dissociation, abuse, and suicidal ideation.
Zuranolone (Zurzuvae) boxed warning
An FDA boxed warning highlighting excessive sedation and severe impairment of driving ability.
Antipsychotic elderly dementia boxed warning
A class-wide FDA boxed warning for all antipsychotics denoting an approximately 1.6–1.7× increase in mortality when used in elderly patients with dementia-related psychosis, alongside a separate warning for cerebrovascular adverse events (stroke/TIA).
SGA metabolic complications
A spectrum of metabolic disturbances including weight gain, diabetes mellitus, and dyslipidemia; highest in severity with olanzapine and clozapine, and lowest with aripiprazole, lurasidone, and cariprazine.
Acute dystonia
An acute extrapyramidal reaction characterized by involuntary, sustained muscle contractions that is treated with benztropine (1–2mg) or diphenhydramine (25–50mg, administered IM for severe cases).
Akathisia
A distressing extrapyramidal syndrome of subjective and motor restlessness, managed primarily by antipsychotic dose reduction or propranolol administration.
Pseudoparkinsonism
A medication-induced movement disorder presenting with rigidity, bradykinesia, and resting tremor, managed by reducing the antipsychotic dose or initiating amantadine.
Tardive dyskinesia
A delayed-onset, potentially irreversible movement disorder causing involuntary choreoathetoid movements, treated with VMAT2 inhibitors (valbenazine, deutetrabenazine).
Antipsychotic hyperprolactinemia
Endocrine dysfunction caused by dopamine receptor antagonism—most pronounced with risperidone and paliperidone—manifesting clinically as galactorrhea, gynecomastia, amenorrhea, and sexual dysfunction.
Antipsychotic orthostatic hypotension
Postural blood pressure drops mediated by alpha-1 adrenergic blockade, most prominently induced by quetiapine, iloperidone, and clozapine.
Aripiprazole signature adverse effects
Adverse reactions stemming from dopamine partial agonism, notably akathisia (inner restlessness) and impulse-control disorders (such as compulsive gambling and spending).
Clozapine boxed warnings
Five major FDA boxed warnings covering agranulocytosis, seizures, myocarditis, other adverse cardiovascular and respiratory effects, and increased mortality in elderly patients with dementia-related psychosis.
Clozapine gastrointestinal hypomotility
A potentially fatal anticholinergic GI complication producing severe constipation and paralytic ileus, requiring a routine prophylactic bowel regimen in older adults.
Clozapine REMS update (2025)
The official FDA removal of the shared Clozapine REMS program in 2025, which retained mandatory absolute neutrophil count (ANC) monitoring as specified by drug labeling.
Neuroleptic Malignant Syndrome (NMS)
A life-threatening neuropsychiatric emergency triggered by antipsychotics (or dopamine-antagonists) presenting with lead-pipe rigidity, hyperthermia, autonomic instability, elevated creatine kinase (CK), leukocytosis, and altered consciousness.
Lithium toxicity stages
A clinical progression of lithium poisoning advancing from mild gastrointestinal upset and fine tremor, to coarse tremor, ataxia, slurred speech, and confusion, culminating in seizures, dysrhythmias, and coma.
Lithium long-term organ complications
Chronic organ damage resulting from long-term lithium therapy, including nephrogenic diabetes insipidus, chronic kidney disease, hypothyroidism, hyperparathyroidism (requiring calcium monitoring), and weight gain.
Valproate boxed warnings
Three primary FDA boxed warnings denoting risks of severe hepatotoxicity, pancreatitis, and teratogenic fetal neural tube defects.
Valproate hyperammonemic encephalopathy
An episode of acute confusion and encephalopathy induced by valproate that can occur despite entirely normal liver transaminases, diagnosed by measuring serum ammonia.
Carbamazepine boxed warnings and screening
Boxed warnings for aplastic anemia, agranulocytosis, and serious cutaneous reactions (SJS/TEN), requiring mandatory HLA-B*15:02 genetic allele screening before initiation in patients of Asian ancestry.
Lamotrigine dermatologic warning
A boxed warning for life-threatening skin rashes (SJS/TEN) that necessitates immediate cessation of the drug upon any rash emergence, strict slow dosage titration, and dose adjustment when paired with valproate (which doubles lamotrigine serum levels).
Topiramate cognitive dulling ('dopamax')
A dose-limiting cognitive adverse effect characterized by psychomotor slowing, word-finding difficulty, and cognitive dulling that restricts its clinical utility in older adults.
Benzodiazepine boxed warnings
FDA boxed warnings emphasizing the high risk of abuse, misuse, and addiction, as well as profound sedation, respiratory depression, and death when co-administered with opioids.
Benzodiazepine withdrawal taper
A gradual discontinuation protocol reducing the daily dose by 5–10% every 2–4 weeks to prevent life-threatening withdrawal seizures.
Complex sleep behaviors
A shared boxed warning for Z-drugs (zolpidem, eszopiclone, zaleplon) describing sleep-walking, sleep-driving, and other complex activities performed while not fully awake.
Stimulant boxed warning and monitoring
A boxed warning highlighting high potential for abuse and dependence, requiring clinical monitoring of blood pressure, heart rate, appetite, and pediatric growth.
Cholinesterase inhibitor cardiovascular risks
Parasympathetic vagal complications of Alzheimer's medications resulting in bradycardia, heart block, and syncope, which pose high risks in sick sinus syndrome or when co-prescribed with beta-blockers.
ChEI-anticholinergic drug interaction
A pharmacodynamically opposing drug combination wherein an anticholinergic agent worsens cognitive function and directly cancels the therapeutic receptor action of a cholinesterase inhibitor.
Serotonin syndrome
A toxic condition arising within 24 hours of combining or escalating serotonergic drugs, characterized by neuromuscular hyperactivity (clonus, hyperreflexia), agitation, diaphoresis, and hyperthermia.
Serotonin syndrome treatment
Emergency management consisting of immediate discontinuation of serotonergic agents, external cooling, intravenous benzodiazepines for agitation, and cyproheptadine administration in moderate-to-severe cases.
Anticholinergic toxidrome
A toxic syndrome remembered by 'hot as a hare, blind as a bat, dry as a bone, red as a beet, mad as a hatter,' presenting with flushed dry skin, tachycardia, mydriasis, urinary retention, and delirium.
Clozapine myocarditis presentation
An early cardiac inflammatory complication manifesting as new-onset fever, tachycardia, chest pain, or dyspnea during the first few months of therapy, demanding urgent ECG and cardiac troponin evaluation.
Neuroleptic-induced dysphagia
An antipsychotic-mediated impairment of swallowing coordination in elderly patients that elevates aspiration pneumonia risk and necessitates meal monitoring and dose tapering.